T cell receptor-like antibodies specific for a PRAME peptide

US11384144B2 · kind B2 · utility

Assignees

• Memorial Sloan Kettering Cancer Center · US
• Eureka Therapeutics, Inc. · US

Inventors

• David A. Scheinberg · New York, US
• Tao Dao · New York, US
• Cheng Liu · Richmond, US
• Hong Liu · Seattle, US
• Yiyang Xu · Pleasanton, US
• Su Yan · Tangxia, CN

Key dates

• Filing date: Nov 20, 2017
• Grant date: Jul 12, 2022
• Expiry date: Jun 21, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/705
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a PRAME peptide/HLA class I molecule complex. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of PRAME associated diseases, including for example, breast cancer, ovarian cancer, melanoma, lung cancer, gastrointestinal cancer, brain tumor, head and neck cancer, renal cancer, myeloma, neuroblastoma, mantle cell lymphoma, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), Non-Hodgkin lymphoma (NHL), and Chronic lymphocytic leukemia (CLL). The antibodies or antigen binding proteins may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.